Analysis of the Availability of Anti-Myeloma Drugs and Impact on the Current Management of Myeloma in Latin American Countries

Filho, Roberto Jose Pessoa de Magalhaes; Crusoé, Edvan; Bujan, Willen; Riva, Eloísa; Arguelles, Guilhermo Ruiz; Cabrera, Juan Ramon Navarro; García, D; Vega, Guilhermo e Quintero; Conte, Guillermo; Macías, José Luis Salcini; Alvear, Jorge Willian Oliveros; Royg, Mercedes; Neves, Lidiane K. Andino; Dopico, Jose Luis Lopez; Espino, German; Ortiz, Douglas Rosales; Socarra, Zurelis; Maiolino, Ângelo; Fantl, Dorotea; Hungria, Vânia; Durie, Brian G.M.

doi:10.1016/j.clml.2017.03.026

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be noted that none of the interviewed physicians used any of the other current treatments for MM, such as carfilzomib and pomalidomide 31 . Our findings confirm that access to new drugs represents a challenge for the reduction of mortality in Latin American countries 4 .…”

Section: Discussionsupporting

confidence: 82%

“…On the other hand, the introduction of modern therapies such as bortezomib has increased the survival of patients with MM 3 , thus increasing the need of giving follow-up to long-term survivors. However, these benefits have been mainly observed in developed countries, while regions such as Latin America (LA) have limited access to novel treatments 1,4 . In Mexico, as in other Latin American countries, there is a need to create adequate epidemiological surveillance tools in order to understand the burden of MM.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The burden of multiple myeloma in Mexico: an epidemiologic investigation of the national health system

Espinoza-Zamora¹,

Figueroa-Acosta²

2022

GAMO

View full text Add to dashboard Cite

Introduction: Although multiple myeloma (MM) represents only 1% of the global burden of cancer, its prevalence increases as the population ages. Monitoring our progress to treat MM requires novel tools for epidemiologic surveillance. Methods: We developed a surrogate measure for the burden of MM in Mexico during 2015, representing the number of prevalent and incident cases of MM at every public and private Mexican health institution. We identified individuals through the ICD-10 codes C90.0-C90.3. Hospitalizations and mortality due to MM were also studied. The number of cases was standardized to represent the age-specific Mexican population obtained through census data. We conducted structured interviews to clini-cians to gather data on treatment and clinical characteristics. Results: In 2015, 2569 patients with MM were attended, 2039 unique patients were hospitalized, and 1169 patients died in the Mexican health system. The incidence rate for MM was 1.16 × 100,000 inhabitants-year during the study period. Therapies were consistent between the public and private sectors. Incidence was higher among elder men. Conclusion: Our findings align with epidemiologic trends in the developing world. As we face aging of the population and new therapies extend the survival of patients with MM, our surrogate will be useful for epidemiologic surveillance.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Introductionmentioning

confidence: 99%